

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zai Lab Limited

再鼎醫藥有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9688)

INSIDE INFORMATION

CHINA'S NATIONAL MEDICAL PRODUCTS ADMINISTRATION APPROVED XACDURO® (SULBACTAM-DURLOBACTAM) FOR HOSPITAL-ACQUIRED AND VENTILATOR-ASSOCIATED PNEUMONIA CAUSED BY *ACINETOBACTER BAUMANNII-CALCOACETICUS COMPLEX*

This announcement is made by Zai Lab Limited (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company is pleased to announce that China’s National Medical Products Administration has approved the New Drug Application for XACDURO® (sulbactam-durlobactam) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, caused by susceptible isolates of *Acinetobacter baumannii-calcoaceticus complex* in patients 18 years of age and older. XACDURO (sulbactam-durlobactam) is an intravenous drug developed by Entasis Therapeutics Inc., an affiliate of Inoviva Specialty Therapeutics, which is a combination of sulbactam, a β -lactam antibiotic, and durlobactam, a β -lactamase inhibitor. The Company has an exclusive license from Entasis Therapeutics Inc. to develop and commercialize XACDURO in Greater China (mainland China, Hong Kong, Macau, and Taiwan, collectively), Korea, Vietnam, Thailand, Cambodia, Laos, Malaysia, Indonesia, the Philippines, Singapore, Australia, New Zealand and Japan.

By Order of the Board

Zai Lab Limited

Samantha Du

Director, Chairperson and Chief Executive Officer

Hong Kong, May 20, 2024

As at the date of this announcement, the board of directors of the Company comprises Dr. Samantha Du as a director, and Dr. Kai-Xian Chen, Dr. John Diekman, Dr. Richard Gaynor, Ms. Nisa Leung, Mr. William Lis, Mr. Scott W. Morrison, Mr. Leon O. Moulder, Jr., Mr. Michel Vounatsos and Mr. Peter Wirth as independent directors.

** For identification only*